Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA.
J Inflamm (Lond). 2013 Aug 10;10(1):28. doi: 10.1186/1476-9255-10-28.
Hypoxia inducible factor-1 (HIF-1) is a major regulator of the cellular adaption to low oxygen stress and the innate immune function of myeloid cells. Treatment with the novel HIF-1 stabilizing drug AKB-4924 has been shown to enhance the bactericidal activity of keratinocytes as well as phagocytic cells. In this study, we sought to investigate the effect of pharmacological boosting of HIF-1 with AKB-4924 in keratinocytes and their contribution to the innate immune response.
Treatment with the novel HIF-1 stabilizing drug AKB-4924 can increase keratinocyte production of pro-inflammatory cytokines in vitro and enhance neutrophil recruitment in vivo.
HIF plays an important role in cytokine production by keratinocytes and in neutrophil recruitment to the skin. The HIF-boosting drug AKB-4924 has the potential to enhance the immune response even in the complex environment of bacterial skin infections.
缺氧诱导因子-1(HIF-1)是细胞适应低氧应激和髓样细胞固有免疫功能的主要调节剂。新型 HIF-1 稳定药物 AKB-4924 的治疗已被证明可增强角质形成细胞以及吞噬细胞的杀菌活性。在这项研究中,我们试图研究用 AKB-4924 药理学增强 HIF-1 对角质形成细胞的作用及其对固有免疫反应的贡献。
新型 HIF-1 稳定药物 AKB-4924 的治疗可增加体外角质形成细胞产生促炎细胞因子,并增强体内中性粒细胞的募集。
HIF 在角质形成细胞产生细胞因子和中性粒细胞募集到皮肤中起重要作用。HIF 增强药物 AKB-4924 即使在细菌皮肤感染的复杂环境中也有可能增强免疫反应。